What was the overall valuation of the India biologics market in 2024?

The overall market valuation was $30.81 Billion in 2024. Read More

What is the projected market valuation for the India biologics market by 2035?

The projected valuation for 2035 is $166.91 Billion. Read More

What is the expected CAGR for the India biologics market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 16.6%. Read More

Which segment had the highest valuation in 2024 within the India biologics market?

Monoclonal Antibodies had the highest valuation at $8.0 Billion in 2024. Read More

What is the projected valuation for the Vaccines segment by 2035?

The projected valuation for the Vaccines segment by 2035 is $35.0 Billion. Read More

Which application segment is expected to grow the most by 2035?

The Infectious Diseases application segment is expected to grow to $40.0 Billion by 2035. Read More

What was the valuation of the Pharmaceutical Companies end user segment in 2024?

The valuation of the Pharmaceutical Companies end user segment was $10.0 Billion in 2024. Read More

What is the projected valuation for the Mammalian source segment by 2035?

The projected valuation for the Mammalian source segment by 2035 is $80.0 Billion. Read More

Which key player is recognized for its leadership in the India biologics market?

AbbVie is recognized as a key player in the India biologics market. Read More

What is the expected growth trend for the Cell and Gene Therapy segment by 2035?

The Cell and Gene Therapy segment is projected to reach $25.0 Billion by 2035. Read More

India Biologics Market

ID: MRFR/MED/43090-HCR

200 Pages

Nidhi Mandole

Last Updated: April 06, 2026

India Biologics Market Research Report: Size, Share, Trend Analysis By Product Service (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others) and By Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others) - Growth Outlook & Industry Forecast 2025 To 2035

India Biologics Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)16.6%

2024 Market Size$ 30.81 Billion

2025 Market Size$ 35.93 Billion

2035 Market Size$ 166.91 Billion

Key Players

Companies such as AbbVie

Roche

Amgen

Johnson & Johnson

Novartis

Pfizer

Trends

Rising Investment in Biologics
Focus on Affordable Healthcare Solutions
Advancements in Regulatory Frameworks

Opportunities

Rising Healthcare Expenditure
Regulatory Support for Biologics
Increasing Demand for Targeted Therapies

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Industrial Automation & Equipment, BY Type (USD Billion) | |
  1. 4.1.1 Monoclonal Antibodies | |
  2. 4.1.2 Vaccines | |
  3. 4.1.3 Cell and Gene Therapy | |
  4. 4.1.4 Recombinant Proteins | |
  5. 4.1.5 Hormones |
2. 4.2 Industrial Automation & Equipment, BY Application (USD Billion) | |
  1. 4.2.1 Oncology | |
  2. 4.2.2 Infectious Diseases | |
  3. 4.2.3 Autoimmune Disorders | |
  4. 4.2.4 Cardiovascular Diseases | |
  5. 4.2.5 Neurological Disorders |
3. 4.3 Industrial Automation & Equipment, BY End User (USD Billion) | |
  1. 4.3.1 Hospitals | |
  2. 4.3.2 Pharmaceutical Companies | |
  3. 4.3.3 Research Institutes | |
  4. 4.3.4 Diagnostics Laboratories |
4. 4.4 Industrial Automation & Equipment, BY Source (USD Billion) | |
  1. 4.4.1 Microbial | |
  2. 4.4.2 Mammalian | |
  3. 4.4.3 Plant | |
  4. 4.4.4 Transgenic Animals 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AbbVie (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Roche (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Amgen (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Johnson & Johnson (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Novartis (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Pfizer (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Merck & Co. (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Bristol-Myers Squibb (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Gilead Sciences (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 INDIA MARKET ANALYSIS BY TYPE |
6. 6.3 INDIA MARKET ANALYSIS BY APPLICATION |
7. 6.4 INDIA MARKET ANALYSIS BY END USER |
8. 6.5 INDIA MARKET ANALYSIS BY SOURCE |
9. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT |
12. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT |
14. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT |
15. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE) |
16. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Billion) |
17. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 (% SHARE) |
18. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 TO 2035 (USD Billion) |
19. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE) |
20. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Billion) |
21. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY SOURCE, 2024 (% SHARE) |
22. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY SOURCE, 2024 TO 2035 (USD Billion) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY SOURCE, 2025-2035 (USD Billion) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

India Biologics Market Segmentation

India Biologics Market By Type (USD Billion, 2025-2035)

Monoclonal Antibodies
Vaccines
Cell and Gene Therapy
Recombinant Proteins
Hormones

India Biologics Market By Application (USD Billion, 2025-2035)

Oncology
Infectious Diseases
Autoimmune Disorders
Cardiovascular Diseases
Neurological Disorders

India Biologics Market By End User (USD Billion, 2025-2035)

Hospitals
Pharmaceutical Companies
Research Institutes
Diagnostics Laboratories

India Biologics Market By Source (USD Billion, 2025-2035)

Microbial
Mammalian
Plant
Transgenic Animals

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”